Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract The transforming growth factor-β (TGF-β) pathway typically inhibits tumorigenesis but can promote metastasis during cancer progression. Activin receptor-like kinase 4 (ALK4), a type I TGF-β family receptor, is frequently downregulated or mutated in cancers, and reduced ALK4 expression correlates with poorer outcomes. However, its role and mechanism of action in cancer progression remains unclear.
Abstract Tumor cells rely on increased glycolytic capacity to promote cell growth and progression. While glycolysis is known to be upregulated in the majority of triple negative (TNBC) or basal-like subtype breast cancers, the mechanism remains unclear. Here, we used integrative genomic analyses to identify a subset of basal-like tumors characterized by increased expression of the oncogenic transcription factor SOX4 and its co-factor the SWI/SNF ATPase SMARCA4.
Invasive lobular carcinoma (ILC) accounts for up to 15% of all invasive breast cancers.1 We have long recognized the unique clinical characteristics of ILC, but an increased understanding of its biology in contrast with the more common breast cancer histologic type, infiltrating ductal carcinoma (IDC), has emerged. The article that accompanies this editorial by Desmedt et al2 reinforces and extends this understanding.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
